Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Walker, J. D
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in diabetic renal disease

James D Walker

Department of Diabetes, Royal Infirmary, Edinburgh, EH3 9YW, UK, james.walker{at}luht.scot.nhs.uk

In mortality terms diabetic nephropathy is the most important microvascular complication of diabetes. Even a small elevation in urinary albumin loss (microalbuminuria) is an independent predictor of end-stage renal failure (ESRF) and death. Detection, confirmation and treatment of diabetic nephropathy are mandatory aspects of diabetes care. Over the last decade a considerable body of evidence has built up suggesting that angiotensin-converting enzyme (ACE) inhibitors are superior to other antihypertensive agents in terms of both renal and overall vascular protection. More recently a number of important studies have reported the beneficial effects of angiotensin receptor antagonists (AIIA) in patients with type 2 diabetes at the stages of microalbuminuria and proteinuria. To date no large studies have directly compared ACE inhibitors with AIIA in patients with diabetic nephropathy. However, given the current state of knowledge, evidence-based therapeutic decisions are possible for individual patients with diabetic nephropathy.

Key Words: angiotensin-converting enzyme (ACE) inhibitors • angiotensin receptor antagonists (AIIA) • diabetic renal disease • hypertension.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 2, 81-84 (2002)
DOI: 10.1177/14746514020020020301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?